Alnylam Statistics, Revenue Totals, Facts & News (2022)
Last Updated on: June 3rd, 2021
Here are a few of the most interesting Alnylam statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Alnylam Facts
- Website: Official Website
- Year Founded: 2002
- Headquarters: Cambridge, MA
- Founder(s): Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, Phillip Zamore, Christoph Westphal and John Kennedy Clarke
- Current Chief Executive: John M. Maraganore
What is Alnylam?
Alnylam is the world’s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. (source)
Alnylam Revenue Totals
Alnylam annual revenue:
- 2019: $219 million
- 2018: $74 million
- 2017: $89 million
- 2016: $47 million
- 2015: $41 million
Alnylam annual net income:
- 2019: $886 million net loss
- 2018: $761 million net loss
- 2017: $490 million net loss
- 2016: $410 million net loss
- 2015: $290 million net loss
Please note that some of these numbers are easier to find than others. A few of these Alnylam stats come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.